AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 52 min read$XERS

Xeris Biopharma Holdings, Inc. (XERS): Submission of Matters to a Vote of Security Holders

Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. xers-20260604 ☐ 0001867096 0001867096 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Jun

Original reporting
SEC EDGAR 8-K
Published Jun 5, 2026, 8:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 8:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$XERS
Neutral
high confidence
Mentioned
$XERS
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$XERSNeutralLow
01

Why it matters

The disclosed items (director election, auditor ratification, and non-binding executive compensation approval) are standard corporate governance matters and do not introduce new financial or operational information.

02

Market read

Confirms governance outcomes; not a catalyst for earnings, guidance, or major corporate actions.

03

What to watch

Traders may be watching for any concurrent proxy contest or board/management changes; this 8-K only reports results and does not describe strategic shifts.

Relevance 6/10Novelty 2/10Timing: Post-annual-meeting filing (June 5, 2026)

Background

The company held its 2026 Annual Meeting of Stockholders on June 4, 2026 and filed an 8-K with the final voting results.

Company-level read

Ticker impact

$XERSNeutralHigh confidence
Context

Xeris Biopharma filed an 8-K reporting final shareholder voting results, including director elections and Say-on-Pay approval.

Expected impact

Likely minimal near-term impact; any move would be sentiment/positioning rather than new fundamentals.

Evidence & confidence

The filing discloses voting tallies (directors, Ernst & Young ratification, non-binding compensation vote) without new financial guidance, deals, or regulatory actions.

Market effects

Sector

No clear sector read-across; governance/auditor ratification is company-specific.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the director election or Say-on-Pay vote margin signals shareholder dissatisfaction, it could foreshadow future governance or compensation changes—though this filing itself is non-binding.

Key entities

  • issuer
    Xeris Biopharma Holdings, Inc.

    Nasdaq-listed company filing the 8-K with final shareholder voting results.

  • auditor
    Ernst & Young LLP

    Ratified by stockholders as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

  • director_nominee
    Dawn Halkuff

    Elected Class II director in the annual meeting vote.

  • director_nominee
    John Johnson

    Elected Class II director in the annual meeting vote.

Read at source← All news

Related articles

AUG 6
$XERSMed

Xeris Biopharma Holdings, Inc. (XERS): Results of Operations and Financial Condition

Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh991q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81

SEC EDGAR 8-K6 min
AUG 9
$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

rttnews.com2 min
AUG 9
$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

rte.ie6 min
AUG 9
$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.

yahoo.com6 min
AUG 8
$MTZMed

Is MasTec’s Debt Raise and Upgraded Guidance Altering The Investment Case For MasTec (MTZ)?

MasTec (MTZ) completed a $647.76 million fixed-rate senior unsecured notes offering with a 5.85% coupon due Sept. 30, 2036. The company reported Q2 2026 sales of $4,373.55 million and net income of $130.12 million, and raised full-year 2026 revenue guidance to $18.2 billion and GAAP net income to $539 million, citing balance-sheet flexibility and governance updates.

simplywall.st6 min